Dr. James P Rougle, DO Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 105 Christopher Ct, Kalispell, MT 59901 Phone: 406-755-6670 |
Dr. Alan Steven Quint, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 17 2nd St E, Suite 206, Kalispell, MT 59901 Phone: 406-755-3148 Fax: 406-755-3499 |
Michael Todd Rutherford, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 75 Claremont St, Suite C, Kalispell, MT 59901 Phone: 406-758-5155 Fax: 406-751-5166 |
News Archive
Alzheimer's disease is caused by the build-up of a brain peptide called amyloid-beta. That's why eliminating the protein has been the focus of almost all drug research pursuing a cure for the devastating neurodegenerative condition.
A study sponsored by Medicaid Health Plans of America (MHPA) released today by The Lewin Group finds large-scale savings can be achieved if 13 states abandoned their current pharmacy carve-out model in favor of a carve-in approach - including prescription drugs in health plans' capitation payments.
Human Genome Sciences has begun dosing patients in a Phase 1 clinical trial of HGS-TR2J, a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.
The current study shows that the sex differences in the tumor phenotype vary with the effect of the enhancer regulatory molecule bound to Brd4 on the course of stem cell-like differentiation in male and female GBM cells. Inhibition of Brd4 by genetic and pharmacological factors also varies in males and females, both in vivo and in vitro.
› Verified 6 days ago